Menu Search
Equities

Anebulo Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
214:FRA

Anebulo Pharmaceuticals Inc

Actions
  • Price (EUR)0.68
  • Today's Change0.00 / 0.00%
  • Shares traded966.00
  • 1 Year change-51.43%
  • Beta-0.7652
Data delayed at least 15 minutes, as of Feb 06 2026 08:55 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. It is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.

  • Revenue in USD (TTM)0.00
  • Net income in USD-8.44m
  • Incorporated2020
  • Employees2.00
  • Location
    Anebulo Pharmaceuticals IncJfl Capital Management1017 Rr 620 S, Suite 107LAKEWAY 78734United StatesUSA
  • Phone+1 (512) 598-0931
  • Websitehttps://www.anebulo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.